After thinking a bit about what Dr Mullan and Dr Chapman said in their webcast, it seems to me they have an enviable problem to solve. Most pharmaceutical companies focus on a specific drug for a specific disease. STSI has the problem of, which disease among the many potential diseases Anatabine solves, gives the biggest bang for the bucks with the least medical and financial risks. He already knows the tolerability and 'side-effect' issue are a slam dunk so he can focus the R&D on efficacy. Since the issue of teaming and/or licensing was not really discussed, this is the billion dollar question whose answer we should anticipate in the near future. I don't think it is lost on Dr Mullan that teaming with a strong financial partner is in the best interest of STSI, especially wherein he can team with an 'expert' company or license in that disease. He knows an agreement is in short order for him to proceed and be successful next year. Right off the bat, it would seem he would entertain teaming or licensing for Alzheimers, Thyroiditis, Multiple Sclerosis, Arthritis, and one or more Cancers or other Autoimmune disorders. Maybe a combination of both worlds. What do you think?
News 
Market Data 
Discover 
